Johnson & Johnson to settle talc baby powder probe

Johnson & Johnson to settle talc baby powder probe

Containers of Johnson and Johnson baby powder are displayed on a Walgreens shelf on April 05, 2023 in San Anselmo, California. Justin Sullivan | Getty Images Johnson & Johnson has reached a tentative settlement to resolve an investigation by more than 40 states into whether the company misled patients about the safety of its talc … Read more

Johnson & Johnson (JNJ) earnings Q4 2023

Johnson & Johnson (JNJ) earnings Q4 2023

The stock trading graph of Johnson & Johnson is seen on a smartphone screen. Rafael Henrique | SOPA Images | LightRocket | Getty Images Johnson & Johnson on Tuesday reported fourth-quarter earnings and revenue that narrowly edged out Wall Street’s expectations as sales in the company’s pharmaceutical and medical devices businesses surged. J&J also provided full-year … Read more

Gilead stock falls after disappointing lung cancer study results

Gilead stock falls after disappointing lung cancer study results

Sopa Images | Lightrocket | Getty Images Shares of Gilead fell more than 9% on Monday after a key drug from the company did not significantly extend the lives of patients with a certain lung cancer in a late-stage trial. The results are a blow to Gilead, which is working to become a power player … Read more

Boehringer Ingelheim, Terns, Viking may join market

Boehringer Ingelheim, Terns, Viking may join market

Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity.  Michael Siluk | UCG | Getty Images Drugmakers have been scrambling to join a two-horse race to lead the market for popular weight loss drugs, which could … Read more

Jim Cramer’s 4 stock ideas from JPMorgan Healthcare Conference

Jim Cramer’s 4 stock ideas from JPMorgan Healthcare Conference

Health care may be a real challenger to tech this year, a business that can actually grow faster than most of tech and has the possibility of a comeback from the Covid straitjacket that so many of these companies got caught up in. The pandemic obscured so much of the growth as Abbott Labs , … Read more

Renewed interest in ADCs will continue in 2024

Renewed interest in ADCs will continue in 2024

Medical personnel use a mammogram to examine a woman’s breast for breast cancer. Hannibal Hanschke | dpa | Picture Alliance | Getty Images SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead. … Read more

Walgreens and 3 other health-care stocks are going into our Bullpen watch list

Walgreens and 3 other health-care stocks are going into our Bullpen watch list

We’re making our first Bullpen update of 2024. The Bullpen is a collection of stocks identified by the CNBC Investing Club team as having the potential to join Jim Cramer’s Charitable Trust. We’re highlighting the four most interesting investment opportunities we found out of the handful of company CEOs Jim interviewed at this week’s JPMorgan … Read more

CVS to close ‘select’ pharmacies in Target stores in the coming months

CVS to close ‘select’ pharmacies in Target stores in the coming months

CVS Health plans to close select pharmacies inside Target stores early this year, a company spokesperson said Thursday, as retail pharmacy chains in the U.S. struggle to boost profits.  The closures will begin in February and finish by the end of April, the spokesperson said in a statement. She added that employees affected by the … Read more

J&J to acquire Ambrx Biopharma, a cancer drug developer, for $2B

J&J to acquire Ambrx Biopharma, a cancer drug developer, for B

An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma, a drugmaker specializing in one of the hottest areas of cancer treatment. … Read more

Moderna Covid vaccine sales plunge in 2023, but meet company forecast

Moderna Covid vaccine sales plunge in 2023, but meet company forecast

Nikos Pekiaridis | Lightrocket | Getty Images Moderna on Monday said its Covid vaccine sales plunged by about two-thirds in 2023 to $6.7 billion, as fewer people rolled up their sleeves for an updated version of the jab. The revenue from the shots met Moderna’s forecast for the year, even as sales plummeted from the … Read more